Hammersmith Medicines Research Ltd

Hammersmith Medicines Research Ltd is a UK-based Clinical Research Organisation focused on conducting Phase 1 and early Phase 2 clinical trials, providing comprehensive services to pharmaceutical and biotechnology sectors globally. Hammersmith Medicines Research Ltd, founded in 1993, operates as a Clinical Research Organisation conducting early-phase clinical trials. Located in London, UK, the company has successfully completed over 900 trials, establishing a strong presence in the clinical research field. The firm has not undergone significant changes in business strategy or operations since its inception.

No information is available regarding subsidiaries or parent companies. The company's founder has not been specifically mentioned in available records. Hammersmith Medicines Research Ltd has been involved in one deal, with the most recent acquisition taking place on August 4, 2025. Hammersmith Medicines Research (HMR) specializes in executing Phase 1 and early Phase 2 clinical trials, offering services like study design, regulatory compliance, subject recruitment, clinical project management, data management, and statistical analysis.

HMR is recognized for its integrated approach, featuring in-house laboratory services, pharmacy, and endoscopy, enhancing trial efficiency and quality. The company caters to pharmaceutical and biotechnology clients worldwide, addressing various therapeutic areas such as cardiovascular, central nervous system, and immunology, and has completed over 900 clinical trials since 1993. Hammersmith Medicines Research generates revenue primarily through contracts with pharmaceutical and biotechnology companies for clinical trial execution. Their revenue model revolves around fee-for-service agreements, which generally include fixed fees and milestone payments linked to trial progress.

HMR's service offerings, particularly its integrated laboratory and pharmacy services, strengthen its competitive position. The pricing structure reflects the complexity of trials and the expertise involved, with long-term relationships with sponsors supporting repeat business and revenue stability in the clinical research market. In August 2025, Hammersmith Medicines Research Ltd was acquired by Nucleus Network, LLC, a portfolio company of Blackstone, to enhance its business development efforts. This acquisition is expected to support the company’s strategy for growth, although specific upcoming products or services have not been detailed.

There are no mentions of planned expansions into new markets or geographic regions at this time.